ClinicalTrials.gg

Program

ocrelizumab

Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.

Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.

Furthest: phase 4, since Jul 5, 201842 company-led studies, 13 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche3810 open or runningphase 4since Jul 5, 2018Feb 12, 2004Dec 31, 2027phase 3 · NCT05269004
Celltrion11 open or runningphase 3since May 9, 2023May 9, 2023Feb 2027phase 3 · NCT05906992
Cinnagen10 open or runningphase 3since Jun 27, 2021Jun 27, 2021none ahead
R-Pharm11 open or runningphase 1since Apr 13, 2026Apr 13, 2026none ahead
Sandoz11 open or runningphase 3since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: ppd-development-lp, laboratory-corporation-of-america and roche-pharma-ag.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Feb 12, 2004.

  1. May 1, 2020Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT04377555 · 179 enrolled · United States, Kenya, Puerto Rico
  2. Sep 4, 20202 phase 3 studies in Multiple SclerosisHoffmann-La Roche · NCT04544436, NCT04548999
  3. Jun 27, 2021Cinnagen's first study: phase 3 study in Multiple SclerosisNew to CinnagenCinnagen · NCT04966338 · 170 enrolled · Iran, Islamic Republic of
  4. Aug 6, 20212 phase 4 studies in Multiple SclerosisHoffmann-La Roche · NCT04998851, NCT04998812
  5. Nov 16, 2021Phase 3 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT05123703 · 188 enrolled · United States, Argentina, Australia and more
  6. Jan 12, 2022Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT05208840 · Russian Federation
  7. Jan 27, 2022Phase 3 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT05232825 · 236 enrolled · United States, Brazil, Czechia and more
  8. Feb 11, 2022Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004 · 1,300 enrolled · United States, Argentina, Australia and more
  9. May 9, 2023Celltrion's first study: phase 3 study in Multiple Sclerosis, Relapsing-RemittingNew to CelltrionCelltrion · NCT05906992 · 512 planned · Poland
  10. Nov 4, 2024Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT06675955 · 500 planned · Bulgaria, France, Germany and more
  11. Feb 19, 2025Sandoz's first study: phase 3 study in Relapsing Multiple SclerosisNew to SandozSandoz · NCT06847724 · 183 enrolled · United States, Bosnia and Herzegovina, Bulgaria and more
  12. Mar 16, 2026Phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450 · 60 enrolled · China
  13. Apr 13, 2026R-Pharm's first study: phase 1 study in Multiple SclerosisNew to R-PharmR-Pharm · NCT07597668 · 180 enrolled · Russia
  14. May 20, 2026Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT07609719 · 100 planned · United States, Puerto Rico

Ahead

  1. Nov 3, 2026Primary completion: phase 3 study in Relapsing Multiple SclerosisSandoz · NCT06847724
  2. Feb 2027Primary completion: phase 3 study in Multiple Sclerosis, Relapsing-RemittingCelltrion · NCT05906992
  3. Dec 31, 2027Primary completion: phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450
  4. Dec 31, 2027Primary completion: phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004

TargetBeta

MS4A1 →read by rule
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07609719Multiple Sclerosis · United States, Puerto Rico4RecruitingHoffmann-La RocheFeb 28, 2029100
NCT07597668Multiple Sclerosis · Russia1Active, not recruitingR-PharmJun 2, 2026180
NCT07483450Multiple Sclerosis, Chronic Progressive · China4Active, not recruitingHoffmann-La RocheDec 31, 202760
NCT06847724Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Bulgaria and more3Active, not recruitingSandozNov 3, 2026183
NCT06675955Multiple Sclerosis · Bulgaria, France, Germany and more3RecruitingHoffmann-La RocheDec 31, 2029500
NCT05906992Multiple Sclerosis, Relapsing-Remitting · Poland3RecruitingCelltrionFeb 2027512
NCT05269004Multiple Sclerosis · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheDec 31, 20271,300
NCT05232825Multiple Sclerosis, Chronic Progressive · United States, Brazil, Czechia and more3CompletedHoffmann-La RocheMar 10, 2023236
NCT05208840Multiple Sclerosis · Russian Federation4WithdrawnHoffmann-La RocheJan 31, 20250
NCT05123703Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheJun 9, 2025188
NCT04998851Multiple Sclerosis · United States, Spain, United Kingdom4CompletedHoffmann-La RocheMar 29, 202426
NCT04998812Multiple Sclerosis · United States, France, Germany and more4CompletedHoffmann-La RocheApr 8, 202470
NCT04966338Multiple Sclerosis · Iran, Islamic Republic of3CompletedCinnagenNov 9, 2020170
NCT04548999Multiple Sclerosis · United States, Argentina, Belgium and more3Active, not recruitingHoffmann-La RocheJun 30, 2025769
NCT04544436Multiple Sclerosis · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheDec 19, 2024864
NCT04377555Multiple Sclerosis · United States, Kenya, Puerto Rico4CompletedHoffmann-La RocheDec 15, 2022179
NCT04075266Multiple Sclerosis · United States, Italy, Poland2Active, not recruitingHoffmann-La RocheOct 5, 202323
NCT04035005Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more3Active, not recruitingHoffmann-La RocheJan 15, 20251,013
NCT03972306Multiple Sclerosis · United States1CompletedHoffmann-La RocheJun 3, 2025134
NCT03606460Multiple Sclerosis · United States3CompletedHoffmann-La RocheMay 31, 2019141
NCT03589105Multiple Sclerosis · France4CompletedHoffmann-La RocheFeb 15, 2021423
NCT03599245Multiple Sclerosis · Argentina, Belgium, Brazil and more3CompletedHoffmann-La RocheJul 17, 20251,055
NCT03523858Multiple Sclerosis, Chronic Progressive · United States, Bosnia and Herzegovina, Brazil and more3Active, not recruitingHoffmann-La RocheOct 22, 2026927
NCT03085810Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more3TerminatedHoffmann-La RocheApr 27, 20231,225
NCT02861014Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Czechia and more3CompletedHoffmann-La RocheOct 25, 2019681
NCT02723071Lymphoma, Non-Hodgkin · Australia, Canada, France and more2CompletedHoffmann-La RocheJan 200848
NCT02720120Arthritis, Rheumatoid · Australia, Belgium, Canada and more2TerminatedHoffmann-La RocheFeb 2013175
NCT02688985Multiple Sclerosis, Chronic Progressive · United States, Canada, Germany and more3CompletedHoffmann-La RocheApr 11, 2023131
NCT02637856Multiple Sclerosis, Relapsing-Remitting · United States, Canada3CompletedHoffmann-La RocheMay 3, 2019608
NCT01412333Relapsing Multiple Sclerosis · United States, Argentina, Belarus and more3CompletedHoffmann-La RocheMay 12, 2015835
NCT01247324Relapsing Multiple Sclerosis · United States, Argentina, Australia and more3CompletedHoffmann-La RocheApr 2, 2015821
NCT01194570Multiple Sclerosis, Chronic Progressive · United States, Australia, Austria and more3CompletedHoffmann-La RocheJul 23, 2015735
NCT00808210Arthritis, Rheumatoid · United States2TerminatedHoffmann-La RocheNov 14, 201228
NCT00779220Arthritis, Rheumatoid · Japan2TerminatedHoffmann-La RocheFeb 2010152
NCT00676715Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more2CompletedHoffmann-La RocheMar 9, 2012220
NCT00673920Arthritis, Rheumatoid3TerminatedHoffmann-La RocheOct 26, 2009314
NCT00626197Lupus Nephritis3TerminatedHoffmann-La RocheOct 19, 2009381
NCT00539838Lupus Erythematosus, Systemic3TerminatedHoffmann-La RocheJul 12, 201133
NCT00485589Arthritis, Rheumatoid3TerminatedHoffmann-La RocheJan 29, 2010613
NCT00476996Arthritis, Rheumatoid · United States, Argentina, Australia and more3TerminatedHoffmann-La RocheJan 21, 2010836
NCT00406419Arthritis, Rheumatoid · United States3TerminatedHoffmann-La RocheOct 6, 20091,015
NCT00077870Arthritis, Rheumatoid2CompletedHoffmann-La Roche237

How it is read

Names in the registry

  • “Ocrelizumab”, 36 entries
  • “ocrelizumab”, 2 entries
  • “CYB704”, 1 entry
  • “OCR SC”, 1 entry
  • “Ocrelizumab SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.